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Abstract
Background: The Long Form and Short Form of the German (original) version of the Urticaria Control Test (UCT)
have shown to be valid and reliable instruments for assessing patients with all types of chronic urticaria (CU). The
cutoff scores for identifying patients with well-controlled disease were ≥ 24 and ≥ 12 for Long and Short Forms,
respectively. However, the sensitivity to change and minimal clinically important difference (MCID) of the UCT have
never been systematically evaluated. This study aimed to investigate the validity, reliability, screening accuracy,
sensitivity to change and MCID of the linguistically validated translation of the UCT into the Thai language for
assessing CU in the Thai population.
Methods: A structured translation and pre-testing were done to cross-culturally adapt the UCT for the Thai
language. All measurement properties of both forms of the Thai UCT were validated in 169 patients with CU.
Results: There were strong correlations between the Thai UCT score and disease activity, health-related quality of
life impairment, and disease control (all correlations ≥ 0.7). Good internal consistency and excellent intra-rater
reliability were demonstrated. The same cutoff scores to define patients with well-controlled disease should be
used as those recommended for the original UCT version. MCIDs equated to increase in scores of 6 and 3 for the
Long and Short Forms, respectively, of the Thai UCT should be used to identify patients who had minimal
responses. Score increments of ≥10 and ≥ 6 for Long and Short Forms, respectively, should be used to define
patients who had marked responses.
Conclusions: This study confirmed the applicability of the UCT for use in Thailand, a country that has a very
different language and cultural setting than that of Germany and the United States. Further studies are required to
examine the suitability of the UCT for use in the pediatric population.
Keywords: Chronic urticaria, Urticaria Control Test (UCT), Minimal clinically important difference (MCID), Reliability,
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Background
Chronic urticaria (CU) is a common debilitating skin dis-
ease which is characterized by the recurrence of wheals,
angioedema, or both for longer than 6 weeks. Its symp-
toms fluctuate considerably from day to day making it dif-
ficult to assess disease activity and treatment response.
Furthermore, it can significantly affect the patients’
health-related quality of life (HRQoL). To follow and treat
patients with CU effectively, it is important to have valid
and reliable tools to capture different dimensions of
disease impact. Over the past decade, several attempts
have been made to create specific instruments that
can be used to evaluate patients with CU globally by
jointly assessing disease activity, HRQoL impairment,
and the use of symptomatic medications [1]. Three
specific questionnaires for CU patients have been de-
veloped including the Urticaria Activity Score (UAS),
the Chronic Urticaria Quality of Life Questionnaire
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(CU-Q2oL) and the Urticaria Severity Score [1–4]. Al-
though the European Academy of Allergology and Clinical
Immunology, Global Allergy and Asthma European
Network, European Dermatology Forum and World
Allergy Organization (EAACI/GA2LEN/EDF/WAO)
guideline recommends the UAS and CU-Q2oL as the
gold standard measurements for evaluating patients
with CU in 2013 [5], both of them still have some
limitations: (i) they are designed only for patients
with chronic spontaneous urticaria, and (ii) they are
not able to use to evaluate disease severity and im-
pact of disease on patients’ HRQoL simultaneously
[1]. In addition, clear cutoff values for the interpret-
ation of their scores are missing.
The Urticaria Control Test (UCT) was devised and
published in 2014 to overcome these limitations. It was
originally developed in the German language and aimed
to assess disease control in all types of CU patients [6].
Two forms of the UCT are available; the Long Form
UCT (8 questions) and the Short Form UCT (4 ques-
tions). Since the results of both UCT forms have been
found to correlate extensively, the Short Form UCT is
sufficient for most settings and primarily recommended
for clinical trials and routine patient care [6]. Each UCT
question has five answer options (0–4 points) regarding
to the disease activity during the past four weeks. The
maximum scores of Long and Short Forms are 32 and
16, respectively. The lower the score is, the lower the
disease control and the higher the disease activity [6].
Previous study has shown that both forms of the original
UCT are valid and reliable instruments for the manage-
ment of patients with CU in clinical practice. The cutoff
scores for identifying patients with well-controlled dis-
ease were ≥ 24 and ≥ 12 for Long and Short Forms, re-
spectively [6]. However, the minimal clinically important
difference (MICD), which is the smallest difference in
score that patients perceive as noticeable improvement,
has never been evaluated. The current study aimed to
investigate the validity, reliability, screening accuracy,
sensitivity to change and MCIDs of the linguistically val-
idated Long Form and Short Form of the newly devel-
oped Thai version of the UCT.
Methods
Translation of the long and short forms of the UCT
questionnaires
The original (German) version of the UCT was inde-
pendently translated into Thai language by two native
Thai speakers with a command of German language.
Then, these two Thai versions were reviewed for com-
prehensibility by dermatologists specialized in allergy.
After these dermatologists reached consensus, the final
Thai version was back-translated into German by two
independent bilingual translators. The back-translated
versions were then reviewed against the originals by the
original authors. Potential misconceptions or misinter-
pretations introduced in the translation process were
discussed between Thai research team and the original
authors. After a consensus on final Thai language ver-
sion was achieved, the Thai version of UCT was tested
in 10 CU patients (cognitive debriefing interviews). Here,
no points of misunderstanding were detected. Subse-
quently, the final Thai version of UCT was administered
for the study.
Clinical measures
(i.)Urticaria Activity Score 28 (UAS28): The UAS28 is a
prospective diary-type patient-reported outcome
(PRO) measure to assess disease activity of CU
patients for four weeks. It sums up the number of
wheals and the intensity of pruritus on a four-point
scale (0–3) with a minimum and maximum score of
0 and 6 points per day, respectively. The UAS28
scores range from 0–168 [2].
(ii.)The validated Thai version of the Chronic Urticaria
Quality of Life Questionnaire (CU-Q2oL): The
CU-Q2oL comprises 23 items categorized into six
domains: pruritus (two items), impact on daily
activities (six items), sleep problems (five items),
limitations (three items), look (five items), and
swelling (two). For each item, patients were asked to
choose between five response options (scored 1–5)
indicating the intensity of each item in the last two
weeks. A total score across all items was calculated
and transformed into scores ranging from 0 to 100,
with a score of 100 indicating the worst possible
HRQoL impairment. The original authors of
CU-Q2oL kindly gave formal permission to Dr.
Kulthanan to validate and use the Thai version of
CU-Q2oL [3, 7].
(iii.)Physician’s global assessment of disease control: The
Physician’s global assessment-visual analog scale
(PhyGA-VAS) is a physician evaluation instrument
for assessing disease control during the last four
weeks. It is a 10-cm unmarked line which ranges
between 0 cm (not at all under control) and 10 cm
(completely under control) [6].
(iv.)Patient’s global assessment of disease severity: the
patient’s global assessment-visual analogue scale
(PatGA-VAS) was used to assess disease severity
during the previous four weeks. The PatGA-VAS is
an unmarked line anchored at the two ends with “no
complaints” (0 cm) and “maximal complaints”
(10 cm) [6].
(v.)Patient’s global assessment of disease control.
Patient’s global assessment-Likert scale (PatGA-LS)
was used to assess treatment sufficiency during the
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previous four weeks. The PatGA-LS is a 5-point
scale for assessing disease control (0 = no control,
1 = little control, 2 = moderate control, 3 = good
control, and 4 = complete control) [6].
Subjects
Thai patients with CU aged 18 years or older attend-
ing Allergy Clinic, Department of Dermatology Siriraj
Hospital were invited to participate and recruited into
the study. Informed consent was obtained from all in-
dividual participants included in the study. Patients
who were not able to read Thai and had other der-
matologic and mental diseases were excluded. All
measurement properties of the validated Thai UCT
were assessed in 168 CU patients. This study (NCT
02285049) was approved by Siriraj Institutional Re-
view Board, Faculty of Medicine Siriraj Hospital. The
ethics approval number is SI 558/2014.
On the first visit (day 0), patients were instructed how
to complete the questionnaires: (i) the validated Thai
version of CU-Q2oL, (ii) the validated Thai version of
UCT, (iii) UAS28, (iv) PatGA-VAS, and (iv) PatGA-LS.
After patients understood how to complete the ques-
tionnaires, they would be asked to complete the UAS28
by themselves prior to the second visit. At the second
visit (day 28), the UAS28 was collected and the validated
Thai version of UCT and CU-Q2oL, PatGA-VAS and
PatGA-LS were completed by the patients at Allergy
Clinic, Department of Dermatolgy, Siriraj Hospital. All
PhyGA-VAS forms were completed by one physician.
Another UAS28 was given to each patient to
complete for 28 consecutive days before coming back
to the hospital on the third visit. The same process
was repeated on the third visit (day 56). During each
visit, the participants received appropriate treatment
according to their disease severity and the EAACI/
GA2LEN/EDF/WAO guideline [5].
Statistical analysis
The methodological quality and statistical analysis of this
study was based on Consensus-based Standards for the
selection of health Measurement INstruments (COS-
MIN) and the Statistical Package for the Social Sciences
(SPSS, Inc., Chicago, IL, USA) version 18 [8].
1. Validity
- Construct validity measures the degree to which a
relevant construct is measured. The correlation
between the validated Thai version of UCT and
CU-Q2oL, UAS28, PhyGA-VAS, PatGA-VAS, and
PatGA-LS were evaluated by Pearson’s correlation
coefficient. Weak, moderate and strong correlations
were defined as correlation coefficient values
of < 0.3, 0.3-0.6, and > 0.6 respectively [9].
- Known-groups validity measures the capacity of
discrimination across groups that are assumed to
differ. The capacity of the Thai UCT to differentiate
patients with different levels of urticaria severity
(UAS28) was explored using Kruskal Wallis test.
The UAS28 scores of ≤10, 11–35, 36–70, 71–105
and ≥106 were used to classify the disease activity of
the patients into none, mild, moderate, severe and
very severe, respectively [6].
2. Reliability
- Internal consistency measures the correlations
among items of measurement. The internal
consistency was determined by Cronbach’s α
reliability coefficient. Excellent, good and acceptable
reliability were defined as α ≥ 0.9, 0.7 ≤ α < 0.9, and
0.6 ≤ α < 0.7, respectively [10].
- Test-retest reliability measures the consistency of
the UCT across multiple administrations. Stable
patients (no change in disease control by PatGA-LS
score during 4-week interval) should display
comparable UCT scores at two different
administrations (2nd and 3rd visits). Intraclass
correlation coefficient (ICC) values of <0.40,
0.40-0.75, and >0.75 were regarded to indicate poor,
average, and strong reliability, respectively [11].
3. Screening accuracy
- Screening accuracy (categorization) is the ability of
UCT to categorize patients into suffering from
poorly-controlled and well-controlled disease.
Patients who had PatGA-LS scores of 0, 1, and 2
were defined as having poorly-controlled urticaria
while patients who had PatGA-LS scores of 3 and 4
were defined as well-controlled. Receiver operating
characteristic (ROC) and area under the curve
(AUC) were used to analyze screening accuracy.
AUCs of 1, 0.9, 0.8, 0.7, and 0.5 were defined as
perfect, excellent, good, fair, and no better than
chance, respectively [12].
4. Sensitivity to change and Interpretability (MCID)
- Sensitivity to change is the ability of the UCT to
detect change over time in the construct to be
measured. As PatGA-LS is a global rating scale
assessing disease control, we expect a positive
correlation between changes in the PatGA-LS and
changes in the Thai UCT score. ROC analysis and
AUC were used to determine the sensitivity to change
of the Thai UCT. The larger the AUC is, the better
the ability of the Thai UCT to detect change [12].
- Interpretability measures the capacity of a
questionnaire to be interpreted from quantitative
scores or change in scores to a qualitative meaning.
The MCID is the minimal difference in a score that
patients recognized as a meaningful improvement
[13, 14]. Three different methods were applied to
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investigate the MCIDs of the validated Thai versions
of the UCT.
(i) Distributional methods look at the statistical
distribution of the instruments values. The standard
error of measurement (SEM) and one-half of
standard deviation (SD) of the measure of interest
are most widely accepted to represent MCID values.
SEM was calculated using SD at baseline of UCT
score × (1-reliability of the validated Thai version of
UCT) 1/2. Distributional methods were used to
derive MCID-1 [15–17].
(ii)ROC analyses determine the sensitivity and
specificity over the range of the absolute reductions
in the Thai UCT score of patients who were
“minimal responders” and “marked responders” [18].
Two criteria: (i) an increase in PatGA-LS score = 1
and (ii) an increase in PatGA-LS score = 2 were
used to define “minimal responders” and “marked
responders”, respectively.
(iii)Anchor-based approaches compare changes in an
instrument’s score with an “anchor” as a reference
[18]. We wished to investigate: (i) the difference in
the mean scores of the Thai UCT between “minimal
responders (an increase in PGA score = 1)” and
“non-responders (no change in PGA score)” and (ii)
the difference in the mean scores of Thai UCT score
between “marked responders (an increase in PGA
score = 2)” and “non-responders (no change in PGA
score and an increase in PGA score = 1)”.
Results
Of 169 patients with CU (mean ± SD age, 42 ± 13.9 years),
132 (78.1 %) patients were female. Chronic spontaneous
urticaria was the predominant diagnosis (98 %). The aver-
age duration of disease was two years ranging from two
months to 34 years. The mean ± SD UCT score at baseline
for Long and Short Forms of Thai UCT were 22.72 ± 6.57
and 10.79 ± 3.36, respectively. A wide distribution of
scores was obtained for each form (Figs. 1 and 2).
Construct and known-groups validity
Tables 1 and 2 demonstrates that both forms of the Thai
UCT showed a strong correlation with disease activity/
severity (UAS28, PatGA-VAS), disease control (PatGA-
LS, PhyGA-VAS) and HRQ2oL impairment (the vali-
dated Thai version of CU-Q2oL). There were statistically
significant differences in UCT scores of patients with dif-
ferent levels of disease severity (p < 0.0001).
Internal consistency and test-retest reliability
The Cronbach’s alpha values of the Long and Short
Forms of Thai UCT were 0.91 and 0.86, respectively
which indicates excellent internal consistency. Thirty-
nine patients who had no change in PatGA-LS scores
during the four-week interval between the 2nd and
the 3rd visit were included to analyze for test-retest
reliability. The ICCs of the Long and Short Forms of
Thai UCT were 0.98 (95 % confidence interval = 0.96-
0.99) and 0.99 (95 % confidence interval = 0.97-0.99)
which demonstrated strong intra-rater reliability of
Thai UCT.
Screening accuracy (Categorization)
Using PatGA-LS, 100 and 94 patients were classified as
having well-controlled disease at 2nd and 3rd visits, re-
spectively. The AUCs on ROC analyses demonstrated
excellent accuracy of both forms of Thai UCT to
categorize patients into having poorly-controlled and
well-controlled disease (Table 3). For the Long Form
UCT, UCT scores of ≥ 24 (sensitivity 84.7 %, specificity
78.7 %) or ≥ 25 (sensitivity 79.6 %, specificity 87.2 %)
were found to be suitable cutoff values to define well-
controlled disease. For the Short Form UCT, UCT scores
of ≥ 11 (sensitivity 90.8 %, specificity 80.9 %) or ≥ 12
(sensitivity 79.6 %, specificity 93.6 %) were suitable cutoff
values to define well-controlled disease.
Sensitivity to change and interpretability (MCID)
The correlations between change in PatGA-LS and Long
Form UCT and between change in PatGA-LS and Short
Form UCT were 0.60 and 0.70, respectively. These
strong correlations indicated that the PatGA-LS can be
used as a construct approach of sensitivity to change
and MCID. The MCID-1 values for the Long Form UCT
were 3.9 (0.5 SD), 2.0 (SEM) using Cronbach’s α value,
and 0.9 (SEM) using ICC value. For Short Form, the
MCID-1 values were 1.7 (0.5 SD), 1.2 (SEM) using
Cronbach’s α value, and 0.3 (SEM) using ICC value.
Table 4 demonstrated a good sensitivity of the Thai
UCT to detect change over time (all AUC ≥ 0.8). On
ROC analyses, the smallest mean changes that identified
“minimal responders” for the Long Form and Short
Form were 3 and 2, respectively. The smallest mean
changes that identified “marked responders” for Long
and Short Forms were 4 and 3, respectively (Table 4).
Table 5 showed that the differences of mean scores be-
tween “minimal responders” and non-responders” were
5.9 and 2.8 for Long and Short Forms, respectively. The
differences of mean scores between “marked responders”
and “non-responders” were 9.6 and 5.8 for Long and
Short Forms, respectively. Therefore, the three different
approaches demonstrated that MCIDs that identified
“minimal responders” and “marked responders”, respect-
ively for the Long Form UCT ranged from 0.9-5.9 and
0.9-9.6. On the other hand, the MCIDs that identified
“minimal responders” and “marked responders” for the
Short Form UCT were 0.3-2.8 and 0.3-5.8, respectively.
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Fig. 1 Distribution of scores of the Long Form of the validated Thai Urticaria Control Test
Kulthanan et al. Health and Quality of Life Outcomes  (2016) 14:61 Page 5 of 9
Discussion and conclusions
The current urticaria guideline clearly recommends that
the aim of treatment should be to achieve complete con-
trol of symptoms. However, none of the previously avail-
able patient reported outcome tools are designed to
detect disease control in patients with CU [5]. This fact
was one major reason why the UCT has been developed.
In addition, the UCT was designed to be (i) a patient-
reported outcome (PRO), (ii) independent of any previ-
ous patient presentations, (iii) easy to administer and
fast to complete, and (iv) easy to score and interpret [6].
The validity, reliability, screening accuracy and feasibility
of the original version has been proved for the original
German version [6]. The reduction of the Long Form to
Table 1 Construct and Known-groups Validity of the Thai-version of the Urticaria Control Test (UCT)
Construct validity (correlations) Urticaria Control Test
Long Form Short Form
Urticaria Activity Score (UAS28) −0.67* −0.68*
Patient’s global assessment of disease severity (PatGA-VAS) −0.81* −0.72*
Patient’s global assessment disease control (PatGA-LS) 0.76* 0.83*
Physician’s global assessment of disease control (PhyGA-VAS) 0.71* 0.77*
Validated Thai version of Chronic Urticaria Quality of
Life Questionnaire (CU-Q2oL)
−0.89* −0.78*
*p value = < 0.0001, r > 0.60 (strong correlation). Please note that some correlations show negative values as higher scores of the UCT (well controlled disease)
indicates lower disease severity (UAS, PatGA-VAS) and negative impact on healh-related quality of life (CU-Q2oL)
Fig. 2 Distribution of scores of the Short Form of the validated Thai Urticaria Control Test
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the Short Form was not found to affect the performance
of the UCT. Thus, the authors of the German version
recommend to use the Short Form in routine clinical
practice and the Long Form in case of additional infor-
mation is required [6]. The German versions were also
translated and linguistically validated for American
English [6].
Our study demonstrated positive strong correlations of
both forms of the Thai UCT with PatGA-LS and
PhyGA-VAS. Notably, both forms of the Thai UCT cor-
related more strongly with PatGA-LS than PhyGA-VAS,
probably because PatGA-LS was a self-assessment of the
patients as is the UCT. In addition, strong negative cor-
relations were found between the Thai UCT and
UAS28, PatGA-VAS, and the validated version of Thai
CU-Q2oL because higher scores of the UCT (well-
controlled disease) indicates lower disease severity
and lower negative impact on HRQoL of patients.
Cronbach’s α and ICC values of the Thai and German
versions of the UCT were comparable which indicated
excellent reproducibility of both versions of the UCT [6,
10, 11]. For screening accuracy, the cutoff values we ob-
tained were very close to those of the original study. In
order to facilitate the use of UCT, we propose that the
Table 2 Construct and Known-groups Validity of the Thai-version of the Urticaria Control Test (UCT)
Known-groups validity Urticaria Control Test
Long Form Short Form
Urticaria Activity Score (UAS28) n of patients Mean (SD) Median n of patients Mean (SD) Median
UAS28≤ 10 55 29.1 (3.3) 30.0 55 14.1 (2.0) 15.0
UAS28 = 11-35 61 24.5 (4.7) 25.0 61 11.5 (2.4) 12.0
UAS28 = 36-70 31 20.0 (5.8) 21.0 31 8.7 (2.8) 9.0
UAS28 = 71-105 14 19.9 (5.0) 20.0 14 8.8 (2.2) 8.0
UAS28≥ 106 8 13.5 (6.9) 14.0 8 5.8 (3.1) 5.0
Please note that some correlations show negative values as higher scores of the UCT (well controlled disease) indicates lower disease severity (UAS, PatGA-VAS)
and negative impact on healh-related quality of life (CU-Q2oL)
Table 3 Cutoff values for the UCT to screening patients for well and poorly controlled disease
Thai UCT score (Long Form) Patient’s global assessment of disease control (PatGA-LS)
2nd visit 3rd visit
Well-controlled patients (n = 100) Well-controlled patients (n = 94)
Sensitivity (%) Specificity (%) Sensitivity (%) Specificity (%)
20.0 75.2 81.3 92.9 44.7
21.0 77.0 76.8 92.9 53.2
22.0 76.8 75.4 89.8 59.6
23.0 81.2 73.5 87.8 68.1
24.0 90.6 72.6 84.7 78.7
25.0 94.6 71.4 79.6 87.2
26.0 95.7 66.0 73.5 93.6
AUC 0.89 (0.84-0.94) 0.90 (0.85-0.95)
Thai UCT score (Short Form) Patient’s global assessment disease control (PatGA-LS)
2nd visit 3rd visit
Well-controlled patients (n = 100) Well-controlled patients (n = 94)
Sensitivity (%) Specificity (%) Sensitivity (%) Specificity (%)
9.0 67.6 93.9 95.9 48.9
10.0 72.6 91.1 93.9 63.8
11.0 76.6 84.5 90.8 80.9
12.0 92.0 84.0 79.6 93.6
13.0 97.0 70.9 61.2 97.9
AUC (95 % CI) 0.93 (0.89-0.97) 0.93 (0.89-0.97)
Abbreviations: AUC (95 % CI): area under the curve (95 % confidence interval)
Bold entries indicate the most important results
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same cutoff values for well controlled- and poorly con-
trolled disease of ≥ 24 and < 24 for Long Form UCT and ≥
12 and < 12 for Short Form UCT, respectively should be
used for the Thai version as those recommended in the
original German version [6].
The sum of weighted scores for the use of antihistamines,
oral glucocorticoids, ciclosporin, hydroxychloroquine and
montelukast has been used to determine disease severity
and treatment outcome of CU patients in several studies.
However, its sensitivity to change and MCID have never
been defined [19–21]. Both sensitivity to change and MCID
are important measurement properties that can be used to
objectively determine treatment outcomes. Moreover, it is
generally accepted that anchor-based methods have higher
clinical relevance and should be preferred to define MCID
rather than statistical distribution-based analysis. For
practical use, we therefore propose that score increments
of 6 and 3 for the Long and Short Forms of Thai UCT,
respectively can be regarded as the smallest increases
that identify “minimal responders” well. Scores increments
Table 4 The MCID by Receiver operating characteristic analysis
Changes in Long Form Thai UCT score Patient’s global assessment of disease control (PatGA-LS) score
Change in score of 1 (minimal responders = 20) Change in score of 2 (marked responders = 9)
Sensitivity (%) Specificity (%) Sensitivity (%) Specificity (%)
1.0 90.0 74.1 100 64.7
2.0 90.0 81.9 100 71.3
3.0 85.0 85.3 88.9 75.0
4.0 70.0 90.5 88.9 81.6
5.0 60.0 94.8 77.8 86.8
6.0 45.0 97.4 77.8 91.2
AUC (95 % CI) 0.86 (0.80-0.98) 0.92 (0.86-0.99)
Changes in Short Form Thai UCT score Patient’s global assessment of disease control (PatGA-LS) score
Change in score of 1 (minimal responders = 20) Change in score of 2 (marked responders = 9)
Sensitivity (%) Specificity (%) Sensitivity (%) Specificity (%)
1.0 80.0 79.3 100 70.6
2.0 75.0 88.8 100 79.4
3.0 60.0 95.7 88.9 87.5
4.0 40.0 97.4 77.8 91.9
5.0 20.0 99.1 77.8 96.3
AUC (95 % CI) 0.84 (0.80-0.97) 0.96 (0.92-0.99)
Abbreviations: MCID minimal clinically important difference, AUC (95 % CI): area under the curve (95 % confidence interval)
Table 5 The differences of mean scores of Thai UCT between minimal and non-responders and between marked and non-responders
Long Form of the Thai UCT

















22.72 (6.57) 24.27 (6.27) 6.5 (7.3) 0.6 (2.7) 11.1 (7.2) 1.5 (2.7)
The differences of mean scores 5.9 9.6
Short Form of the Thai UCT

















10.79 (3.31) 11.31 (3.36) 3.0 (2.7) 0.2 (1.3) 6.3 (2.7) 0.6 (1.9)
The differences of mean scores 2.8 5.8
Abbreviation: SD standard deviation
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of ≥10 and ≥ 6 for Long Form and Short Form Thai UCT,
respectively may be used to identify “marked responders”.
Conclusions
This study cleary confirms the usefulness of the UCT
to assess disease control and to guide treatment deci-
sions in patients with chronic urticaria in the Thai
population, which can be considered quite different in
terms of the cultural setting and the language spoken
from the German and US-American populations the
original UCT has been developed for. Moreover, this
study adds important new information to help in the
interpretation of UCT results. For the first time, sen-
sitivity to change and interpretability have been con-
firmed and defined. We are convinced that both
forms of the UCT are valid and reliable patient re-
ported outcome instruments for use in routine clin-
ical practice and clinical trials in European, North
American and Asian countries. Since the UCT has
been developed for adults, further studies are required
to examine the UCT in children and adolescents.
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